Pre-Clinical Research

Found 9,157 articles

• Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

  5/8/2023

  Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced an upcoming poster presentation at IMMUNOLOGY2023™.

• Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

  5/6/2023

  Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the presentation of clinical and preclinical data for IMU-856.

• Microbot Medical Announces Final Data From Its Recent Animal Study

  5/5/2023

  Microbot Medical Inc., the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, has received the histopathology report from the European-based MedTech research laboratory that performed the animal study for the LIBERTY Robotic System in October 2022.

• Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

  5/4/2023

  Epic BIO announced the acceptance of an abstract for oral presentation at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy taking place May 16-20, 2023, in Los Angeles, Calif.

• LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids

  5/4/2023

  LIfT BioSciences today announces preclinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMAN) showed potent killing of pancreatic cancer tumouroids.

• SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

  5/4/2023

  SNIPR Biome ApS ("SNIPR") announces today that Nature Biotechnology has published research findings from its preclinical work on  SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, in the human gastrointestinal tract.

• Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

  5/3/2023

  Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) today announced that its pre-clinical manuscript entitled “Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (GLP-2), Teduglutide - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome” has been accepted for publication by the International Journal of Peptide Research and Therapeutics.

• Affinia Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting

  5/3/2023

  Affinia Therapeutics today announced that new preclinical data will be presented in an oral and poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023 in Los Angeles, CA.

• Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma

  5/2/2023

  Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray.

• Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

  5/2/2023

  Dyne Therapeutics, Inc. (Nasdaq: DYN) today announced that new preclinical data demonstrating the FORCE™ platform achieved delivery to the central nervous system (CNS) and robust pharmacological effects in the brain will be featured in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.

• 2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

  5/1/2023

  2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program.

• Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

  5/1/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego.

• Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors

  4/27/2023

  Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.

• Yuyu Pharma, Dry Eye Pipeline Mechanism of Action and Pre-clinical Results Published

  4/27/2023

  At ARVO 2023, Yuyu Pharma unveiled the results of its mechanism of action and head-to- head studies for its dry eye treatment peptide.

• Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

  4/27/2023

  Arbutus Biopharma Corporation announced that clinical data for AB-729, an RNAi therapeutic, and preclinical data for AB-161, a next-generation oral HBV specific RNA destabilizer, were presented as late-breaker oral presentations at the Global Hepatitis Summit 2023 in Paris.

• Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting

  4/26/2023

  Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that transverse tissue barriers to selectively target activated cells in regions of inflammation, today announced two preclinical data sets demonstrating the efficacy of its anti-angiogenic precision nanomedicine, D-4517.2.

• Uvax Bio Announces Publication of Results from Preclinical Studies of HIV Vaccine Candidates

  4/26/2023

  Uvax Bio , LLC today announced that its HIV vaccine candidates have shown significant improvement in immune response compared with current vaccine strategies.

• J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC

  4/26/2023

  J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held in Orlando, USA from April 14 to 19.

• Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis

  4/25/2023

  Pan-Biome Pharmaceuticals, Inc, is pleased to announce that its lead compound exhibited protective effects in a preclinical model of inflammatory colitis. 

• BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

  4/25/2023

  BetterLife Pharma Inc. announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience in Ottawa, Canada, will present on the anti-depressant and anti-anxiety activity of BetterLife’s 2-bromo-LSD at the upcoming SOBP Conference, being held April 27-29, 2023 at San Diego, California, USA.